Simpson Thacher represented Global Blue on the deal. Homburger advised Certares Opportunities LLC and Knighthead Opportunities Capital Management, LLC. Global Blue Group Holding AG announced their […]
Global Blue’s $225 Million Growth Equity Investment From Certares and Knighthead
Kering’s Sale of Ulysse Nardin & Girard-Perregaux in a Management Buyout
Vischer advised the management of the Sowind group. Homburger advised Kering on the transaction. Kering entered into an agreement for the sale of its entire stake […]
BlueVoyant’s Cyber-Defense Joint Venture With Elca
Homburger advised BlueVoyant on the deal, while Bär & Karrer advised ELCA. The American cybersecurity service provider Bluevoyant and the Swiss IT provider ELCA announced the creation […]
Coinbase’s Acquihire of BRD
Homburger acted as Swiss counsel to Coinbase. Coinbase (Nasdaq: COIN), a leading provider of end-to-end financial infrastructure and technology for the cryptoeconomy, announced its acquihire of BRD, […]
FNZ’s Acquisition of Appway
Bär & Karrer acts as legal advisor to the founding shareholders of Appway in this transaction. Goodwin Procter advised Summit Partners. Homburger advised FNZ in this […]
CSL’s A$16.4 Billion Acquisition of Vifor Pharma
Homburger AG, Bär & Karrer, Simpson Thacher & Bartlett LLP, and Allens acted as joint legal advisors to CSL. PJT Partners, BofA Securities and Goldman Sachs […]
KKR’s Investment in Biosynth Carbosynth
Sidley, Homburger and Wolf Theiss advised KKR on the deal. Bär & Karrer acts as legal advisor to Armira and Dr. Urs Spitz in this transaction. […]
anthera Pharmaceuticals’ CHF 15 Million Private Convertible Bonds And CHF 10 Million Exchangeable Notes
Homburger advised Santhera in this matter. Santhera Pharmaceuticals annouced a strengthening of its capital structure via placement of private convertible bonds of CHF 15 million and upsizing of […]
Santhera Pharmaceuticals’ CHF 20 Million Shares Private Placement
Pestalozzi advised H.C. Wainwright on the deal. Homburger advised Santhera. Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular […]
On Holding AG’s Initial Public Offering at NYSE
Lenz & Staehelin advised On Holding AG on the deal. Homburger advised the underwriters. On Holding AG, a Swiss-based athletic shoe and performance sportswear company, successfully […]
SOPHiA GENETICS’ $234 Million Initial Public Offering on Nasdaq
Homburger and Davis Polk advised SOPHiA GENETICS on the deal. Lenz & Staehelin acted as Swiss counsel to the underwriters. SOPHiA GENETICS SA listed its shares […]
Molecular Partners’ $63.8 Million Initial Public Offering in The US and Listing on NASDAQ Close
Homburger advised Molecular Partners AG in the transaction, while Davis Polk and Advestra advised the joint book-running managers and representatives of the underwriters. Molecular Partners AG, […]